Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

This study of 49 patients with spontaneous venous and arterial thrombosis identified 27 with hypercoagulable states: 13 had only venous thrombosis (VT), six had episodes of VT followed by arterial thrombosis (AT) and eight had AT only. All 27 patients were less than 42 years of age; 22 had specific natural anticoagulant or fibrinolytic deficiencies: antithrombin III (nine patients), protein C (eight patients), protein S (three patients), heparin cofactor II (two patients), tissue plasminogen activator release (one patient) and mixed antithrombin III and protein S (one patient). The remaining five patients had recurrent thrombotic events associated with resistance to heparin anticoagulation, but no established laboratory diagnosis. Clotting complications included recurrent VT, pulmonary embolism, multiple failed arterial procedures and lower extremity amputation. The remaining 22 patients (mean age of 53 years, range of 46 to 63 years), 12 with VT and ten with AT, did not have laboratory evidence of hypercoagulability and none had recurrent vascular occlusions. All these patients were successfully treated by conventional therapy without any additional thrombotic events during the follow-up period. Young adults with spontaneous thrombotic events should be screened for possible hypercoagulable states. Additionally, these young patients need further evaluation and treatment of cardiovascular risk factors. Those with premature atherosclerosis have an especially poor prognosis despite surgical intervention and anticoagulant therapy.
 ...
PMID:Hypercoagulable states as an evolving risk for spontaneous venous and arterial thrombosis. 792 7

We report the case of a woman treated with urokinase for acute pulmonary embolism with a right-sided heart thrombus. She developed life-threatening acute cor pulmonale which dramatically improved within 4 h with recombinant tissue plasminogen activator (rtPA). We emphasize the clinical interest of rtPA for the treatment of life-threatening pulmonary embolism.
 ...
PMID:Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator. 816 78

A minority of patients with acute pulmonary embolism (PE) show failure of resolution when assessed by serial ventilation/perfusion (V/Q) radionuclide lung imaging. The fibrinolytic systems were studied in six such patients (group I), and in 11 patients in whom PE had resolved (group II), together with 17 healthy control subjects. Assays of the fibrinolytic system included euglobulin clot lysis times (ECLT), tissue plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1). Euglobulin clot lysis times were not prolonged in the unresolved PE group, but were significantly longer in patients in group II when compared to control subjects (P < 0.03). This could not be explained either on the basis of tPA levels, which were higher in group II when compared to group I (P < 0.05) and control subjects (P < 0.02), or on the basis of PAI-1 levels which did not differ significantly between the three groups. Our inability to demonstrate derangements of fibrinolysis in the patients with unresolved PE makes defective fibrinolysis an unlikely aetiological factor in the persistence of thrombosis in these patients.
 ...
PMID:Unresolved pulmonary embolism: the role of fibrinolysis. 842 33

We evaluated retrospectively the clinical indicators for the treatment of 15 patients with severe pulmonary embolism. All patients had moderate or severe pulmonary hypertension with deteriorated oxygenation. Thrombolytic agents and catecholamines were administered and mechanical ventilation was performed so as to treat right heart failure and improve oxygenation. In 14 patients, the pulmonary artery pressure decreased gradually and PaO2 increased in response to these therapies. The 14 patients were discharged from ICU without any symptoms. One patient died of cerebral hemorrhage due to the side effects of tissue plasminogen activator. We conclude that the pulmonary artery pressure and PaO2 are useful indicators for the treatment of the early phase of severe pulmonary embolism. Moreover, timely use of cetecholamine is very important for the maintenance of pulmonary circulation and acceleration of thrombolysis.
 ...
PMID:[Retrospective analysis of 15 cases with severe pulmonary embolism]. 843 61

We report the clinical, echocardiographic and therapeutic aspect of one case of right cardiac migrant thromboembolus in pulmonary embolism. Medical therapy consisted of tissue plasminogen activator (rt-PA, 100 mg/3h). Progressive reduction of thromboembolus until its disappearance was observed by echo 2D after this therapy. Ec 2D may be an important test in diagnosing pulmonary embolism when perfusion lung scans (extremely sensitive but non specific test) or pulmonary angiography (the most accurate test) are not available at hospital and patient cannot be transferred for his critical illness.
 ...
PMID:[Dissolution of a right cardiac migrant thromboembolus in pulmonary embolism after treatment with rt-PA. Report of a successfully treated case]. 845 Oct 30

Pulmonary embolism must often be considered as a differential diagnosis, especially in the perioperative period. Only prompt therapeutic measures can reduce the high early mortality in the acute phase of this condition. Diagnostic and therapeutic measures are dependent on the severity of the symptoms. If pulmonary embolism is suspected, heparin is administered. In the case of cardiovascular deterioration, other measures have to be taken. Following confirmation of the diagnosis of pulmonary embolism, several thrombolytic regimens are applicable. Low-dose urokinase (bolus 250,000 U followed by 60,000-80,000 U/h) is associated with a relatively low incidence of bleeding complications. A more rapid reduction of the right ventricular afterload will be achieved via short-term thrombolysis. Newer findings suggest that bolus thrombolysis with 3 million U urokinase is as effective as 100 mg tissue plasminogen activator (rt-PA) administered over a 2-h period. When the patient is found to be in a state of shock, confirmation of the diagnosis has to be delayed. Recommendations include the bolus application of 1.5-3 million U urokinase when right ventricular decompensation is prominent or during cardiopulmonary resuscitation. In case of existing contraindications or postoperatively, low-dose urokinase treatment (bolus 250,000 U followed by 40,000-60,000 U/h, rarely up to 2,200 U/kg per hour) may be initiated when the situation is urgent and there are no treatment alternatives. Bolus application of 1-2 million U urokinase should be considered depending on the severity of the symptoms and the underlying disease. In some hospitals, alternative treatment modalities include catheter-assisted procedures with subsequent local thrombolysis and surgical embolectomy. Pathophysiological aspects as well as therapeutic options in the intensive care unit are discussed in depth. In addition to adequate oxygenation, right ventricular coronary perfusion and contractility may be maintained using various catecholamine infusions. The importance of phosphodiesterase inhibitors, mediator antagonists such as acetylsalicylic acid or ketanserin, and dilators of the pulmonary vascular bed are discussed.
 ...
PMID:[Acute thromboembolism of the lung. Clinical picture--pathophysiology--diagnosis--therapy]. 847 Jul 87

The 4 widely available thrombolytic agents, alteplase (recombinant tissue plasminogen activator, rt-PA), anisoylated plasminogen streptokinase activator complex (APSAC; anistreplase), streptokinase and urokinase have revolutionised the treatment of acute myocardial infarction and are also effective in treating pulmonary embolism and peripheral arterial thrombosis. Therapeutic efficacy of the agents appears to be similar. Choice of a thrombolytic agent depends more on patient characteristics, availability and familiarity with the drug, cost and differences in tolerability. While overall thrombolytic therapy is relatively safe, these 4 agents differ in their tolerability profiles. Streptokinase has the lowest cerebral haemorrhage rate, anistreplase an intermediate and alteplase the highest rate. The incidence of total stroke is also higher with alteplase and anistreplase than with streptokinase, translating to an actual difference in patient risk of 4 extra strokes per 1000 patients treated. Risk of major bleeding is dependent on predisposing factors and seems to be similar with each agent. The incidence of hypotension with alteplase (4.3% in ISIS-3) is less than with streptokinase or anistreplase (6.8 and 7.2%, respectively in ISIS-3). The incidence of major anaphylactic reactions with streptokinase and anistreplase is low (< 1%). Urokinase and alteplase may be preferred for readministration of thrombolytic therapy and anistreplase is the agent of choice where rapid completion of therapy is desirable. The various agents may have different tolerability profiles with different adjunctive therapies and further data are therefore required.
 ...
PMID:Comparative tolerability profiles of thrombolytic agents. A review. 847 Nov 85

We report here a case of thromboembolism occurring in a 29-year-old woman with transient eosinophilia. Eosinophilia for at least 11 days was followed by pulmonary embolism. Both reperfusion of pulmonary arteries and disappearance of deep vein thrombi were obtained by treatment with urokinase, tissue plasminogen activator, and heparin. Although the causes of eosinophilia were not specified, we suggested a causative correlation of elevated serum levels of eosinophil granule proteins with the development of thromboembolism.
 ...
PMID:Thromboembolism in a patient with transient eosinophilia. 859 15

The main complication of totally implantable venous access devices is deep venous thrombosis on catheter. It may dramatically reduce the already limited venous capacity of patients undergoing chemotherapy and obturate catheters, causing pulmonary embolism or functional disorders. These thromboses usually involve veins of the superior vena cava system where the catheters are implanted. Generally, they occur early, are extensive and often asymptomatic. Doppler ultrasonography is the diagnostic investigation of choice, phlebography being reserved for particular cases or to specify the limits of the thrombus. In a series of 412 vein access devices implanted and systematically monitored by Doppler ultrasonography, we found 57 thromboses (13.8%), 15 partial and 42 complete. The lowest thrombosis rate was observed in the right internal jugular vein (10% vs 20 to 23%, p = 0.006). Thirty-two patients received a systemic fibrinolytic treatment, 16 with streptokinase (SK), five with urokinase (UK), four with tissue plasminogen activator (rt-PA) and seven with SK/UK association. No serious side effects were observed. Sixteen repermeabilizations (50% of fibrinolysis) were obtained. There were no significant differences with respect to the fibrinolytic, the initial characteristics of thrombosis or the patients. Patients without fibrinolysis received 3 weeks of low molecular weight heparin (curative doses) then warfarin. Only one patient was repermeabilized with this treatment (significative difference with fibrinolysis: p = 0.009). Fibrinolysis is indicated in symptomatic thrombosis and/or in cases of extension to the innominate vein or the superior vena cava. Systematic monitoring by Doppler ultrasonography and prophylactic anti-thrombotic treatment are recommended in patients with implantable venous access devices in order to decrease the occurrence of thromboses, to detect asymptomatic patients at an early stage and to increase the effectiveness of fibrinolysis.
 ...
PMID:[Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis]. 868 80

Pulmonary embolism is an often underestimated, underdiagnosed, and undertreated disease. As symptoms and signs of pulmonary embolism are nonspecific, the diagnosis still remains a challenge to the attending physician. Diagnostic and therapeutic procedures depend on the clinical presentation of the patient. First we must suspect pulmonary embolism and consider its likelihood in the presence of a number of clinical signs and symptoms. Once pulmonary embolism is suspected, heparin should be administered. Additional basic support is mandatory if required. If the patient's hemodynamic situation is stable, available preferable noninvasive diagnostic options should be considered to confirm or rule out the diagnosis of venous thromboembolism before further administration of anticoagulant or thrombolytic agents. If the patient's status has deteriorated, bedside diagnostic techniques should be applied to reinforce the suspicion or establish the diagnosis. To restore pulmonary perfusion more rapidly than conventional anticoagulation is suspected to do, several dosing regimens of thrombolytic agents are proposed, with recent interest in short-term thrombolysis and bolus lysis with urokinase or recombinant tissue plasminogen activator. If thrombolysis fails or is contraindicated, catheter embolectomy or surgical embolectomy is indicated. The main therapy is prevention. In this article, clinical assessment, imaging techniques, and therapeutic options described in the published literature are discussed and clinical experiences of an emergency department with a noninvasive diagnostic approach are described.
 ...
PMID:Pulmonary embolism. II. Diagnosis and treatment. 871 89


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>